Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Subscribers have five weeks to nominate their company and their innovations in the Animal Pharm Awards for 2018.
Kindred Biosciences believes it is ahead of competitors in developing its interleukin-31 (IL-31) antibody.
Zoetis has gained US FDA approval for its Cyden (clopidol) and Lincomix (lincomycin) combination feed additive.
Ceva Santé Animale's Isemid (torasemide) has moved a step closer to European authorization after gaining a recommendation for marketing approval.
Japanese authorities have revealed the extent of human Capnocytophaga infections over the last 24 years.
Dômes Pharma has made an equity investment in fellow family-owned French company StemT Laboratory – a specialist in the veterinary stem cell therapy sector.
Taiwan-based firm Vetnostrum is aiming to diversify its portfolio of veterinary generics in the near future, by moving further into the companion animal sector.
Singapore-based Credo Biomedical is seeking global partners to take its point-of-care (POC) molecular diagnostics for companion animals to a wider sales base.
Zoetis is to add to its Revolution (selamectin) canine parasiticide brand next year, by bringing a new product to market in the US.
Zoetis is to add new companion animal products to its Chinese portfolio in the coming years, as the firm looks to build on the growth its swine vaccines have initiated.
Kindred Biosciences has gained positive top-line results from a pilot effectiveness study of its interleukin-31 (IL-31) antibody for the treatment of canine atopic dermatitis.
Phyto Animal Health has signed an exclusive distribution agreement with Liiv Organics to sell its cannabidiol (CBD) products in the US.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.